News

Novo Nordisk joins finance’s great one-hit wonders
In the near term, commercial efforts might raise the chances that new patients are prescribed Novo Nordisk’s drug, assuming ...
Novo Nordisk rode Ozempic’s success to becoming Europe’s top company. Now it’s faltering and its CEO is out.
Lars Fruergaard Jorgensen, the chief executive of once-highflying Danish drugmaker Novo Nordisk, is stepping down after eight ...
Ozempic-Maker CEO Ousted Over Pharma Company’s Rocky Market Downturn
In an abrupt and surprising twist, the CEO of Ozempic-maker Novo Nordisk has been ousted from his position as the head of the ...
Novo Nordisk's CEO is out after the Ozempic maker's stock dropped 50% in a year
CEO Lars Fruergaard Jørgensen will step down after eight years at the helm of the Danish pharmaceutical giant responsible for ...
Long Island patients lost vision after taking weight loss drugs Ozempic and Wegovy, lawsuits contend
The lawsuits come amid several recent studies showing a link between vision complications and people taking drugs ...
Blocked From Selling Off-Brand Ozempic, Telehealth Startups Embrace a Less Effective Drug
As the FDA halts the sale of Ozempic and Zepbound copycats, online clinics have begun offering liraglutide, an older GLP-1 ...
New York Post4d
Ozempic maker Novo Nordisk ousts CEO amid plunging share price as rival Eli Lilly gains market share
Ozempic and Wegovy maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market.
Ozempic Maker Novo Nordisk Looks For New Chief, Jørgensen Steps Down From CEO Role
Novo Nordisk CEO steps down after pressure from shareholders. Former CEO to join board as observer. Company remains ...
Novo Nordisk Woes Just Hit Denmark’s Economy. The Stock Is Rising.
That’s a bit harsh given Denmark’s strong growth compared with neighboring countries over the past few years has been largely ...